Dr Bob Soh

Meet Proxima Bio: Australia's next-generation biotech startup aiming to clean up cancer-causing proteins.

Profile of Australian biotech startup Proxima Bio, covering its founding, an early MRFF grant through the CUREator program, Brandon Capital's guidance, and a later larger investment that grew the team.

Glyscend Therapeutics commences South Australia Phase I clinical trial to progress new type 2 diabetes treatment

Glyscend Therapeutics, a Johns Hopkins spin-out, is starting a Phase I trial of its type 2 diabetes pill in Adelaide; the piece recalls its AUD$29 million Series A led by Brandon Capital's MRCF.

Also Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio

Innovative type two diabetes treatment scores $29m

Glyscend's diabetes pill has raised $29 million with backing from Brandon Capital, Santé Ventures and Breakout Labs, ahead of planned human trials in Adelaide.

Also Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio